Carbon-Ion Radiotherapy Plus Camrelizumab With or Without Apatinib for Locally Recurrent Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Carcinoma Interventions:   Radiation: Carbon-ion radiotherapy;   Drug: Camrelizumab;   Drug: Apatinib Sponsor:   Shanghai Proton and Heavy Ion Center Not yet recruiting

Source: ClinicalTrials.gov - October 30, 2019 Category: Research Source Type: clinical trials